Protocol Number: 09-C-0038
-The vaccine used in this study, called DC CMV pp65, is made from special immune cells called DCs, which are made using the patient's own white blood cells. -The DCs contain genetic material that instructs the cells to make a protein called CMV that is found in the patient's tumor. Objectives: -To learn if the DC vaccine can help activate the patient's immune system against the CMV protein and stimulate it to fight the brain tumor cells. Eligibility: -Adult patients with a newly diagnosed glioblastoma multiforme tumor. Design: -Patients continue treatment with Avastin and temozolomide (TMZ) -Patients undergo apheresis to collect white blood cells for use in making the vaccine. For this procedure, a catheter is inserted into a vein in each arm. Blood flows from one arm into a machine that separates and extracts the white cells, and the rest of the blood is returned to the patient through the catheter in the other arm. -Patients receive three vaccine injections - one every 2 weeks for the first 6 weeks of the study. The vaccine is injected just under the skin on both sides of the groin. -Patients have follow-up visits for the following procedures: -Review of side effects or symptoms -Blood draw to check kidney function and immune function -Brain MRI to assess tumor -Treatment may continue until the Avastin and TMZ no longer control the tumor or treatment side effects are no longer tolerable.
Search The Studies | Help | Questions |
National Institutes of Health Clinical Center |
||